Reports
Sale
Nocturia Market Size, Share, Growth, Analysis, Forecast: By Disease Type: Polyuria, Nocturnal Polyuria, Low Nocturnal Bladder Capacity, Mixed Nocturia; By Drug Type: Anti-cholinergic, Desmopressin, Antibiotic, Anti-spasmodic, Others; By Dosage Form: Tablet, Nasal Spray; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Nocturia Market Outlook
The nocturia market size was valued at USD 3.3 billion in 2023, driven by the rising prevalence of nocturia across the 8 major markets. The market is expected to grow at a CAGR of 8.3% during the forecast period of 2024-2032, with the values likely to rise from USD 3.5 billion in 2024 to USD 6.6 billion by 2032.
Nocturia Market Overview
Nocturia is a medical condition characterized by excessive urination at night, with the affected individual visiting the bathroom twice or more at nighttime. Patients with nocturia can suffer from sleep deprivation which can greatly impact the quality of life. It is also linked with obesity, depression, diabetes, and heart disease, among others.
The market is driven by the rising prevalence of nocturia, with over 50% of men and women aged 60 or more reported to be diagnosed with the condition. The incidence of nocturia in older men is higher than in older women, amounting to 50% in men between 70 to 79 years having two or more nightly voids. The growing number of patients with nocturia is expected to directly drive the nocturia market demand, with more and more individuals seeking effective treatment options to manage the symptoms.
As people age, they are more likely to experience nocturia, which also tends to become more severe. With the rising geriatric population, clinically significant nocturia cases are expected to surge. According to the United Nations Population Fund, the number of older people aged 60 years, or more is expected to reach 2.1 billion worldwide, accounting for 22% of the total population. Moreover, it is estimated that the elderly population in India will double, almost reaching 347 million in 2050. This indicates that the rapid growth of the geriatric population is likely to augment nocturia market share in the coming years.
The market is also supported by increased research initiatives aimed at finding innovative treatment solutions to treat nocturia. In April 2023, a randomized controlled trial revealed the potential of Erbium YAG laser treatment to manage overactive bladder, often accompanied by frequent urination and nocturia. The study showed positive results, with women receiving the intervention reporting less nocturia and urination urgency, along with additional benefits. The development of such novel treatment methods is anticipated to boost nocturia market growth.
Other factors that impact the market dynamics include the growing technological advancements in diagnostic tools and digital health applications for monitoring symptoms and treatment efficacy. Rising healthcare expenditure, and the introduction of advanced therapies also impact the market significantly. Moreover, the market is expected to witness increased demand owing to the high prevalence rate of chronic conditions such as obesity and hypertension that make an individual prone to nocturia.
Nocturia Market Trends
| Key Trends | Impact |
| Advancements in Treatment Options | Technological advancements coupled with pharmaceutical progressions have led to the development of new and improved treatment options for nocturia. From behavioral interventions to pharmacotherapy and surgical procedures, the rising accessibility of these therapeutic interventions is fuelling the nocturia market share. Further, the market is witnessing a diversification of available treatments, which attracts a wider patient base, thereby driving market demand. |
| Integration of Digital Health Technologies | The integration of digital health technologies, such as mobile apps for bladder monitoring and telehealth services for remote consultations, is significantly impacting the market landscape. With the help of these digital tools, patient management along with adherence to treatment plans are likely to improve. This market trend follows a patient-centric approach by leveraging digital solutions, focusing on the convenience of the patients, and is expected to bolster nocturia market demand in the coming years. |
| Heightened Awareness and Diagnosis | The rising awareness among the public and healthcare professionals about nocturia as a treatable condition, rather than a normal part of aging, has accelerated diagnosis rates and encouraged treatment-seeking behaviour. Moreover, this trend also supports ongoing research and development aimed at finding effective therapeutics to treat nocturia, contributing to market growth and innovation in the healthcare sector. |
| Rising Healthcare Expenditure | One of the significant nocturia market trends is the increased healthcare expenditure that enables substantial investment in the diagnosis and treatment of nocturia. This is expected to accelerate the development of advanced therapies more accessible to a broader patient population. This financial investment also supports the adoption of innovative medical technologies, further driving market growth. |
Nocturia Market Segmentation
Market Breakup by Disease Type
- Polyuria
- Nocturnal Polyuria
- Low Nocturnal Bladder Capacity
- Mixed Nocturia
The market is segmented by disease type into polyuria, nocturnal polyuria, low nocturnal bladder capacity, and mixed nocturia. In about 88% of patients , the cause of nocturia is nocturnal polyuria which is characterized by greater production of urine during nighttime.
Market Breakup by Drug Type
- Anti-cholinergic
- Desmopressin
- Antibiotic
- Anti-spasmodic
- Others
In terms of drug type, the market comprises anti-cholinergic drugs, desmopressin, antibiotics, anti-spasmodic, and other medications targeting various aspects of nocturia management. This market segment reflects the range of medications usually prescribed for treating nocturia. For instance, desmopressin is an antidiuretic that is usually given to nocturia patients to reduce the amount of urine produced.
Market Breakup by Dosage Form
- Tablet
- Nasal Spray
The nocturia market share by dosage forms includes tablets and nasal sprays. This segment offers different administration options according to specific patient needs and convenience.
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Drug Store
- Retail Pharmacies
- Online Pharmacies
Distribution channels for nocturia drugs are hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. This segment provides various facilities or healthcare settings for patients to access medications.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Based on the region, the nocturia market segmentation includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. United States holds a significant portion of the market which can be attributed to the high prevalence rate of the disease in the region. It is estimated that 50 million individuals are affected by the condition, which can severely impact the overall health and daytime functioning of the patient. The rising number of nocturia cases along with heightened patient awareness and diagnostic rates are expected to drive the market demand in the regional market.
Nocturia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Urigen Pharmaceuticals
- Glenmark Pharmaceuticals
- AbbVie Inc.
- Teva Pharmaceuticals
- Avadel Pharmaceuticals
- Astellas Pharma
- Dainippon Sumitomo Pharma
- Feering Pharmaceuticals
- AA Pharma Inc.
- Pfizer Inc
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Drug Type |
|
| Breakup by Dosage Form |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Nocturia Market Report
- How has the market performed so far and how will it perform in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of nocturia affect the market landscape?
- How does the rise in the geriatric population impact the nocturia market size?
- What disease type will dominate the market share?
- Which dosage form is expected to have a high market value in the coming years?
- Which drug type will experience the highest demand in the market segment?
- Which distribution channel will significantly impact market growth?
- How will the ongoing clinical trials impact the market value during the forecast period?
- What are the factors driving regional disparities in nocturia treatment and outcomes?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Nocturia Market Overview – 8 Major Markets
3.1 Nocturia Market Historical Value (2017-2023)
3.2 Nocturia Market Forecast Value (2024-2032)
4 Nocturia Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Nocturia Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Nocturia Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Nocturia Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Nocturia Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Nocturia Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Nocturia Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Nocturia Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Nocturia Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Nocturia Epidemiology Scenario and Forecast (2017-2032)
6.5 India Nocturia Epidemiology Scenario and Forecast (2017-2032)
7 Nocturia Market Landscape – 8 Major Markets
7.1 Nocturia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Nocturia: Product Landscape
7.2.1 Analysis by Disease Type
7.2.2 Analysis by Drug Type
7.2.3 Analysis by Dosage Forms
8 Nocturia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Nocturia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Nocturia Market Segmentation (2017-2032) - 8 Major Markets
11.1 Nocturia Market (2017-2032) by Disease Type
11.1.1 Market Overview
11.1.2 Polyuria
11.1.3 Nocturnal Polyuria
11.1.4 Low Nocturnal Bladder Capacity
11.1.5 Mixed Nocturia
11.2 Nocturia Market (2017-2032) by Drug Type
11.2.1 Market Overview
11.2.2 Anti-cholinergic
11.2.3 Desmopressin
11.2.4 Antibiotic
11.2.5 Anti-spasmodic
11.2.6 Others
11.3 Nocturia Market (2017-2032) by Dosage Form
11.3.1 Market Overview
11.3.2 Tablet
11.3.3 Nasal Spray
11.4 Nocturia Market (2017-2032) by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacies
11.4.3 Drug Store
11.4.4 Retail Pharmacies
11.4.5 Online Pharmacies
11.5 Nocturia Market (2017-2032) by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
11.5.5 India
12 United States Nocturia Market (2017-2032)
12.1 United States Nocturia Market Historical Value (2017-2023)
12.2 United States Nocturia Market Forecast Value (2024-2032)
12.3 United States Nocturia Market (2017-2032) by Disease Type
12.3.1 Market Overview
12.3.2 Polyuria
12.3.3 Nocturnal Polyuria
12.3.4 Low Nocturnal Bladder Capacity
12.3.5 Mixed Nocturia
12.4 United States Nocturia Market (2017-2032) by Drug Type
12.4.1 Market Overview
12.4.2 Anti-cholinergic
12.4.3 Desmopressin
12.4.4 Antibiotic
12.4.5 Anti-spasmodic
12.4.6 Others
13 EU-4 and United Kingdom Nocturia Market (2017-2032)
13.1 EU-4 and United Kingdom Nocturia Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Nocturia Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Nocturia Market Overview
13.4 EU-4 and United Kingdom Nocturia Market (2017-2032) by Disease Type
13.4.1 Market Overview
13.4.2 Polyuria
13.4.3 Nocturnal Polyuria
13.4.4 Low Nocturnal Bladder Capacity
13.4.5 Mixed Nocturia
13.5 EU-4 and United Kingdom Nocturia Market (2017-2032) by Drug Type
13.5.1 Market Overview
13.5.2 Anti-cholinergic
13.5.3 Desmopressin
13.5.4 Antibiotic
13.5.5 Anti-spasmodic
13.5.6 Others
14 Japan Nocturia Market
14.1 Japan Nocturia Market Historical Value (2017-2023)
14.2 Japan Nocturia Market Forecast Value (2024-2032)
14.3 Japan Nocturia Market (2017-2032) by Disease Type
14.3.1 Market Overview
14.3.2 Polyuria
14.3.3 Nocturnal Polyuria
14.3.4 Low Nocturnal Bladder Capacity
14.3.5 Mixed Nocturia
14.4 Japan Nocturia Market (2017-2032) by Drug Type
14.4.1 Market Overview
14.4.2 Anti-cholinergic
14.4.3 Desmopressin
14.4.4 Antibiotic
14.4.5 Anti-spasmodic
14.4.6 Others
15 India Nocturia Market
15.1 India Nocturia Market (2017-2032) Historical Value (2017-2023)
15.2 India Nocturia Market (2017-2032) Forecast Value (2024-2032)
15.3 India Nocturia Market (2017-2032) by Disease Type
15.3.1 Market Overview
15.3.2 Polyuria
15.3.3 Nocturnal Polyuria
15.3.4 Low Nocturnal Bladder Capacity
15.3.5 Mixed Nocturia
15.4 India Nocturia Market (2017-2032) by Drug Type
15.4.1 Market Overview
15.4.2 Anti-cholinergic
15.4.3 Desmopressin
15.4.4 Antibiotic
15.4.5 Anti-spasmodic
15.4.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Urigen Pharmaceuticals
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Glenmark Pharmaceuticals
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 AbbVie Inc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Teva Pharmaceuticals
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Avadel Pharmaceuticals
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Astellas Pharma
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Dainippon Sumitomo Pharma
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Feering Pharmaceuticals
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 AA Pharma Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Pfizer Inc.
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
23 Nocturia Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 3.3 billion in 2023 driven by the rising prevalence of nocturia across the 8 major markets.
The market is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032, likely to reach a market value of USD 6.6 billion by 2032.
The market demand is driven by heightened patient awareness and rising healthcare expenditure.
One of the significant trends in the market is increased research initiatives aimed at finding innovative treatment solutions to treat nocturia. In April 2023, a trial revealed the potential of Erbium YAG laser treatment to manage overactive bladder, often accompanied by frequent urination and nocturia.
Based on the disease type, the market is segmented into polyuria, nocturnal polyuria, low nocturnal bladder capacity, and mixed nocturia.
Based on the drug type, the market is segmented into anti-cholinergic drugs, desmopressin, antibiotics, anti-spasmodics, and other medications.
Various dosage forms in the market are tablets and nasal sprays.
Distribution channels in the market include hospital pharmacies, drug stores, retail pharmacies, and online pharmacies.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India.
Key players involved in the market are Urigen Pharmaceuticals, Glenmark Pharmaceuticals, AbbVie Inc., Teva Pharmaceuticals, Avadel Pharmaceuticals, Astellas Pharma, Dainippon Sumitomo Pharma, Feering Pharmaceuticals, AA Pharma Inc., and Pfizer Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER